Hongchao Pan, PhD, on an Update on 5 Years of Endocrine Therapy for Early Breast Cancer
2019 San Antonio Breast Cancer SymposiumHongchao Pan, PhD, of the University of Oxford, discusses an analysis of 86,000 women in the Early Breast Cancer Trialists’ Collaborative Group database, which showed that the risk of distant recurrence 20 years after a diagnosis of node-negative, estrogen receptor–negative early-stage breast cancer in women who discontinued endocrine therapy at 5 years is likely to be about a third lower now than in his group’s previous report (Abstract GS2-04).
Related Videos
Joseph Sparano, MD: The William L. McGuire Memorial Lecture
Joseph Sparano, MD, of the Montefiore Medical Center, discusses three challenges:
- How can gene-expression profiles and other diagnostic tests be ...
Joerg Heil, MD, PhD, on Image-Guided Vacuum-Assisted Breast Biopsy
Joerg Heil, MD, PhD, of the University Hospital Heidelberg, discusses findings on how accurately this technique can diagnose residual disease and pathologic complete response...
Jack Cuzick, PhD, on the International Breast Cancer Intervention Study II: 10-Year Results
Jack Cuzick, PhD, of Queen Mary University of London, discusses the substantially greater benefits of anastrozole as compared with tamoxifen in terms of preventing breast can...
Rashmi K. Murthy, MD, on HER2-Positive Metastatic Breast Cancer: HER2CLIMB Trial of Tucatinib, Capecitabine, and Trastuzumab
Rashmi K. Murthy, MD, of The University of Texas MD Anderson Cancer Center, discusses data on the efficacy and safety of tucatinib, trastuzumab, and capecitabine, a treatment...
Marie-Jeanne T.F.D. Vrancken Peeters, MD, PhD, on Omitting Breast Surgery: Results of the MICRA Trial
Marie-Jeanne T.F.D. Vrancken Peeters, MD, PhD, of the Netherlands Cancer Institute, discusses an interim study analysis showing that ultrasound-guided core biopsies of the br...
